In partnership with Ablatotech, we are developing the first small molecule drug that has been shown to reverse arterial dilatations (aneurysms) and is also effective for reversing enlargement of the heart. We believe our patented small molecule regimen will be a game-changer in cardiovascular health.
Also, in partnership with Ablatotech, we are developing the first rapid treatment for deep vein thrombosis (DVT) and other blood clotting conditions. Unlike the current blood-thinner regimens that require a lifetime of use, our therapy is not a blood thinner and it dissolves the clot safely in hours. It is the first therapy of its kind for the treatment and prevention of DVT and other blood clotting conditions.
While other drug discovery companies are wasting a lot of time and resources with the high throughput method of small molecule drug discovery, which is mostly responsible for the ridiculous costs in drug discovery, we prefer a smarter medicinal anthropology approach. In our approach, we start with a single compound, as opposed to thousands or millions of compounds, and develop it into a safer and more efficient drug.